Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Pricing in additional dilution
View:
Post by Greenviolino on Jul 08, 2022 4:38pm

Pricing in additional dilution

Less than a year for the company to figure out how it's going to reimburse the convertible deb. The stock price might reflect the worst-case scenario of having to issue shares at current price - roughly 15-20 million, or additional 15% dilution. Let's hope the financials improve in the meantime and we get news on Th-1902.
Comment by Wino115 on Jul 08, 2022 4:59pm
The path depends on Phase 1b.  But the options they've discussed include partnering oncology asset (either region like China, or indication they aren't interested in although that would be later), debt for debt -- just take on more at higher rate to repay if you see positive signs in the trial. I agree the stock seems to incorporate all bad news and next to no good news, which is ...more  
Comment by juniper88 on Jul 08, 2022 5:52pm
I was told that in these types of trials you need at least 20 patients in a tumor type to get one response. I'll give you 2 more pieces of info that I heard. 1) they will expand the number of patients from about 70 to 125. 2) Three patients in 1b that went before my wife have stable disease at this site. From what Iunderstandafter 1 scan. I have no info on other sites. I suppose I go through ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities